SCHEMBL30830514

SCHEMBL30830514

Cc1c(N[C@@H]2C[C@H](c3ccc(CN4CCN(c5ccc(F)c(C6CCC(=O)NC6=O)c5)CC4)cc3)CN(C)C2)cnn(C)c1=O

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ KAT2B Q92831 17/20 0.41
▸ BRD9 Q9H8M2 3/20 0.41
▸ BRD1 O95696 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ BRPF1 P55201 1/20 0.39
▸ BPTF Q12830 1/20 0.39
▸ KAT2A Q92830 1/20 0.39
▸ BRD7 Q9NPI1 1/20 0.39
▸ BAZ2B Q9UIF8 1/20 0.39
▸ BRPF3 Q9ULD4 1/20 0.39
▸ PLK4 O00444 1/20 0.36
▸ CRBN Q96SW2 2/20 0.34
▸ IKZF3 Q9UKT9 2/20 0.34
▸ DDB1 Q16531 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30830912 0.94 KAT2B (0.49) KAT2BBRD9
SCHEMBL30830743 0.93 KAT2B (0.49) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831086 0.91 KAT2B (0.41) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830511 0.89 KAT2B (0.46) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830862 0.88 KAT2B (0.47) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831039 0.88 KAT2B (0.41) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830978 0.88 KAT2B (0.42) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830831 0.88 KAT2B (0.40) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30830554 0.87 KAT2B (0.49) KAT2BBRD9BRD1ACHEBRPF1
SCHEMBL30831011 0.85 KAT2B (0.42) KAT2BBRD9BRD1ACHEBRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4581025-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS Auron Therapeutics, Inc. (US) 2025-07-09 — — EP disclosed
WO-2024050078-A1 PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS AURON THERAPEUTICS, INC. (US) 2024-03-07 — — WO disclosed
Send feedback